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Abstract
Introduction: Approximately 70% of bladder cancers are non-muscle-invasive (NMIBC), and respond well
to endoscopic transurethral resection. However, 70% of these patients experience tumor recurrence. As the
tendency for local recurrence and/or progression extends over the lifetime, patients with superficial bladder
cancer must undergo life-long surveillance. Combination of cystoscopy and urine cytology is considered
the “gold standard” for this surveillance. However, they suffer from drawbacks where cystoscopy is an
invasive procedure and urine cytology shows limited ability to detect low grade bladder tumors. Therefore,
new non-invasive tests with high sensitivity and specificity that are easy to perform are needed not only for
initial diagnosis but also in surveillance for recurrent tumors.
Objective: To investigate the magnitude investigate the magnitude of survivin expression in non-muscle-
invasive bladder cancer and its possible value as a non invasive diagnostic tool.
Patients and methods: From March 2010 to October 2010, 68 patients with known history of NMIBC who
were scheduled for follow-up cystoscopy in the department of Urology, Alexandria University were included
in this study prospectively. All patients underwent cystoscopy under general anaesthesia, and those who
were found to have a definite or suspicious lesion(s) in the bladder underwent complete TURBT. Survivin
urine and in bladder cancer tissue both by Western blotting and by ELISA.
8 patients. Tumor recurrence was detected in 38 patients, of whom, 24 had
ary concentration of survivin was significantly higher in the recurrence groupexpression was determined in
Results: The study included 6
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by both detection methods (U = 141, P = 0.018 and χ2 = 10.46, P = 0.001 for ELISA and WB respectively).
Survivin by ELISA showed higher sensitivity and specificity (84.4% and 100%) than that by WB (55.3%
and 93.3%). In tumor tissue, by both methods, survivin was detected in higher levels than in urine but there
was no significant correlation between urinary and tissue levels neither in the whole recurrence group nor
in the low grade subgroup.
Conclusion: Urinary survivin is a useful marker for non-invasive detection of non-muscle-invasive bladder
cancer recurrence. Its detection is better using ELISA technique than WB and there is no correlation between
its expression in tissue and urine.
© 2012 Production and hosting by Elsevier B.V. on behalf of Pan African Urological Surgeons’ Association.
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pproximately 70% of bladder cancers are non-muscle-invasive
NMIBC), and respond well to endoscopic transurethral resection.
owever, 70% of these patients experience tumor recurrence [1,2].
s the tendency for local recurrence and/or progression extends over
he lifetime, patients with superficial bladder cancer must undergo
ife-long surveillance [3,4]. Combination of cystoscopy and urine
ytology is considered the “gold standard” for this surveillance.
owever they suffer from drawbacks where cystoscopy is an inva-
ive procedure [5] and urine cytology shows limited ability to detect
ow grade bladder tumors [6]. Therefore, new non-invasive tests with
igh sensitivity and specificity that are easy to perform are needed
ot only for initial diagnosis but also in surveillance for recurrent
umors [7,8].
urvivin is a bifunctional protein that regulates cell division and sup-
resses apoptosis. It is the smallest member of inhibitor of apoptosis
IAP) family of proteins. Although it is abundantly expressed in fetal
issues [9], it is undetectable in most normal, terminally differenti-
ted adult tissues. However, survivin is over-expressed in a variety
f human cancers, suggesting that reactivation of the survivin gene
requently occurs in cancers [10]. The cancer-specific expression of
urvivin, coupled with its importance in inhibiting cell death, and
n regulating cell division, makes it a useful diagnostic marker of
ancer and a potential target for cancer treatment [11].
he aim of this work was to investigate the magnitude of survivin
xpression in non-muscle-invasive bladder cancer and its possible
alue as a non invasive diagnostic tool.
atients and methods
rom march 2010 to October 2010; all patients with known history
f NMIBC who were scheduled for follow-up cystoscopy in the
epartment of Urology, Alexandria University were included in this
tudy prospectively. After getting the approval of the ethical com-
ittee in our institution, a well informed written consent was signed
y the patient to collect a fresh voided morning urine sample, a piece
f the resected tumor and to obtain the necessary clinical and patho-
ogical data from his medical records. Approximately 50–100 ml of
orning voided urine sample was collected aseptically from every
atient.
Open access under CC BY-NC-ll patients underwent cystoscopy under general anaesthesia, and
hose who were found to have a definite or suspicious lesion(s) in
he bladder underwent complete TURBT and the specimen was sent
or histopathological assessment.
a
p
a
aoided urine samples were taken before cystoscopy, a portion of
hich was aliquoted into two epindorf tubes (1.5 ml each) and stored
t −20 ◦C till the time of the assay of urinary survivin concentrations
y ELISA technique [12], and the remaining portion was divided
nto 5 ml aliquots in non adsorption modified tubes and then stored at
70 ◦C until time of analysis of survivin by Western blot technique
13].
umor tissue specimens were obtained from patients by
ransurethral resection (TUR) and were histologically verified. Stag-
ng and grading according to the union international contre le cancer
UICC) [14] and 2004 WHO criteria [15] was carried out by an
xperienced pathologist. Fresh tissues were stored immediately at
70 ◦C until preparation of the sample used for survivin protein
uantification by both ELISA and Western blot analysis.
tatistical analysis
ata were fed to the computer using the Predictive Analytics Soft-
are (PASW Statistics 18). Qualitative data were described using
umber and percent. Association between categorical variables
as tested using Chi-square test. The distributions of quantitative
ariables were tested for normality using Kolmogorov–Smirnov
est which revealed abnormal distribution of the data. Thus, non-
arametric statistics were applied. Quantitative data were described
sing median, minimum and maximum as well as mean and standard
eviation. Mann–Whitney was used to compare between two sam-
les. Correlations between two quantitative variables were assessed
sing Spearman’s rho test. The diagnostic performance of survivin
xpression was evaluated using Receiver Operating Characteristic
ROC) curve analysis. Kappa statistic was performed to determine
onsistency between survivin in urine and in tissue. Significance
f the obtained results was judged at the 5% level. It is quoted as
wo-tailed probabilities.
esults
rom March 2010 to October 2010, 68 patients were eligible to our
tudy. Thirty patients were found to have no recurrence of the disease
ense.nd were considered as group I (recurrence-free group) while 38
atients had non-muscle-invasive recurrence and were considered
s group II (recurrence group). Demographic data of both groups
re presented in Table 1.
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Table 1 Demographic data of all patients.
Group G1 G2
Recurrence-free Recurrence
No. 30 38
Age 34–72 39–7644 ± 5 49 ± 8
Sex
Male 18 22
Female 12 16
Grade
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Urinary survivin
We evaluated the potential diagnostic value of survivin detection in
urine using two methods: ELISA and WB analysis
By ELISA
Urinary survivin concentration of the recurrence-free group ranged
from 6.30 to 23.50 pg/ml (median: 17.30) with a mean value of
15.53 ± 5.20 pg/ml, while its range was from 12.10 to 183.60 pg/ml
(median: 69.70) in the recurrence group with a mean value of
78.90 ± 49.77. Statistical comparison between the median values
of survivin in the two studied groups using the non parametric
Mann Whitney U test showed a significant difference (U = 141.00,
P = 0.018) indicating a significant association between its level and
bladder cancer recurrence (Table 2).
Although, the median values were approximately two times higher
in group Ib (high grade bladder tumor) than group Ia (low grade
bladder tumor), a non significant difference was found between the
two groups (U = 81.00, P = 0.087) (Table 2).
At the best cut off value for survivin, the sensitivity was 84.37%
and the specificity was 100% (Fig. 1 and Table 3). Among the low
grade subgroup, survivin showed a true-positive rate of 58.3% (14
out of 24 patients were above the cut off value 23.5 pg/ml) while in
the high grade subgroup 13 out of 14 were above the cut off value
(positivity rate of 92.9%).By Western blot
The positivity rate for survivin in the voided urine samples of the
recurrence-free group was 2/30 (6.7%), while the positivity rate
in the recurrence group was 21/38 (55.3%). Statistical comparison
h
A
m
d
Table 2 Survivin expression in the two groups by both techniques.
Group 1 N = 30
Survivin
By
ELIZA
Mean 15.53 ± 5.2
Median 69.7 (12.1–1836.6)
Mean
Median
Survivin
By
WB
+ve/−ve 2/28
Posetivity 6.7%
+ve/−ve
Posetivity
* Significant at P < 0.05.n of recurrence 145
etween the positivity rates of urinary survivin in the two studied
roups using non parametric chi-square test showed a significant dif-
erence (χ2 = 10.46, P = 0.001) indicating a significant association
etween its expression and bladder cancer recurrence. However, a
on significant difference was found between group IIa (low grade)
nd group IIb (high grade) (χ2 = 2.34, P = 0.126) (Table 2).
he overall sensitivity and specificity of urinary surviving detection
y WB for predicting bladder cancer recurrence were 55.26% and
3.33% respectively (Table 3).
ur findings revealed that urinary survivin levels detected by ELISA
nd WB were significantly associated with bladder cancer. However,
n a direct comparison of both survivin protein detection assays,
he survivin ELISA showed a higher sensitivity and specificity than
urvivin WB but the difference does not reach statistical significance
differences between areas = 0.121, P = 0.080) (Table 3 and Fig. 1).
issue survivin
n our study, we investigated the expression of survivin in bladder
umor tissue samples by both ELISA and WB. The tumor tissue
evel of survivin by ELISA ranged from 15.00 to 2108.00 pg/ml
median = 437.75) with a mean value of 1022.42 ± 1061.74 pg/ml.
n the other hand, survivin protein was detected by WB in tumor
issue of 27 patients with tumor recurrence with a positivity rate of
1.1%.
lthough the median levels of survivin were approximately 6 times
igher in tumor tissue than in urine, no significant correlation was
bserved between urine and tissue levels neither in the whole malig-
ant group nor in the low grade subgroup. However, a significant
ositive correlation was found between tissue and urinary levels of
urvivin in the high grade group (r = 0.645, P = 0.013) (Table 4 and
ig. 2). Similar correlations were reported for survivin WB (Table 5).
iscussion
eregulation of apoptosis is a hallmark in human carcinogenesis,
nd bladder cancer has been shown to resist programmed cell death
ith altered expression of pro and anti-apoptotic proteins [16]. Sur-
ivin, a member of the inhibitor of apoptosis protein (IAP) family,
as a very important role in apoptosis and control of cell division.
t the same time it is selectively expressed in malignant versus nor-
al tissues. These two characteristics make survivin an excellent
iagnostic biomarker in bladder cancer [17].
Group 2 N = 38 Test
G2a N = 24 G2bN = 14
78.9 ± 49.77 U = 141
P = 0.018*17.3 (6.3–23.5)
60.9 115.6 U = 81
P = 0.08712.1–136.1 13.6–183.6
21/17 χ2 = 10.46
P = 0.001*55.3%
11/13 10/14 χ2 = 2.34
P = 0.12645.8% 71.4%
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Figure 1 Comparison between the diagnostic performance of both survivin ELISA and WB: AUC equals 0.900 and 0.743 respectively.
Table 3 Comparison between the diagnostic performance of survivin ELISA and WB determined by ROC analysis.
Parameter AUC (95% CI) P-value Cut-off value Sen. (95% CI) Sp. (95% CI) PPV (95%
CI)
NPV (95%
CI)
Diff. between
areas (P-value)
Survivin ELISA pg/ml (urine) 0.900
0.777–0.968
0.0001 >23.5 84.37
67.2–94.7
100.00
78.0–100.0
100.0 75.0 0.121 (.080)
Survivin WB (urine) 0.743
0.604–0.853
0.0005 55.26
38.3–71.4
93.33
68.0–98.9
95.5 45.2
Table 4 Correlations between tissue and urinary levels of survivin.
S in T by
ELISA
S in U by
ELISA
Group 2 N = 38 437.75
(15.00–3404.00)
69.7
(12.00–183.00)
rs = 0.243
P = 0.142
Group 2a N = 24 322.50
(15.00–3404.00)
60.90
(12.10–136.10)
rs = 0.022
P = 0.920
Group 2b N = 14 881.40
(93.40–2908.00)
115.60
(13.60–183.60)
rs = 0.645
P = 0.013
Figure 2 Correlations between tissue and urinary levels of survivin.
Expression of surviving in non-muscle-invasive bladder cancer: Detectio
Table 5 Agreement between tissue and urinary expression of sur-
vivin WB in group I, group Ia and group Ib patients.
Agreement
No. (%)
No agreement
No. (%)
Kappa
(P-value)
Group I 24 (63.16) 14 (36.84) 0.299 (0.135)
Group IaLow grade 12 (50.00) 12 (50.00) 0.020 (0.916)
Group IbHigh grade 12 (85.71) 2 (14.29) 0.588* (0.016)
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cells [29]. Therefore, our results, consistent with the studies dis-* Significant at P < 0.05.
In the current study, we investigated survivin protein expression in
both tumor tissue and urine samples using ELISA, confirmed by
Western blotting WB. A strong expression of survivin protein was
detected by ELISA in all 38 tumor tissue samples. Additionally,
71% (27/38) of the investigated tissue samples showed detectable
amounts of survivin by WB. Taken together, our data revealed strong
survivin protein expression in bladder tumor tissues indicating that
this protein might play an important role in carcinogenesis of the
human urinary bladder.
The results of this study were in agreement with those of Wu et al.
[18], who reported high survivin protein expression detected by
Western blot analysis in 76.6% of bladder tumor tissue extracts
and no detectable levels in normal tissues. Similarly, Xiao et al.
[19], reported the expression of survivin protein in tumor tis-
sues derived from patients with TCC of the urinary bladder
and that it was significantly associated with tumor grade. In
line with the previous finding, Swana et al. [20] and Ku et al.
[21], revealed a high incidence of survivin protein expression
in bladder cancer tissue using immunohistochemical-staining. In
addition, Schultz et al. [22] reported an elevated survivin mRNA
expression in urothelial cell carcinomas determined by RT-PCR
assays.
Moreover, no significant association between survivin expres-
sion and tumor grade was found in the present study, which
disagrees with Swana et al. [20], who reported that survivin
detection correlated closely to high tumor grade. However, con-
sistent with our results, Ku et al. [21], failed to detect a
correlation between survivin expression and tumor grade in 88
non-muscle invasive bladder tumors. The discrepancy in results
may reflect differences in the methods used to detect sur-
vivin.
Based on the fact that many tumor associated or derived
molecules are potentially released into the urine when it
comes in contact with the tumor, many non invasive urine
based immunoassays have been designed to measure these
molecules for detecting bladder cancer [23]. As survivin is
selectively expressed in malignant epithelium and in the same
time present in detectable levels in urine, it is considered as
an attractive urinary biomarker for detection of bladder cancer
[17].
In the early work by Smith et al. [24], urinary survivin protein and
mRNA had a sensitivity of 100% and specificity of 95% in the
detection of new or recurrent cases of bladder cancer. In a large
study by Shariat et al. [12], higher levels of survivin were found to
correlate with an increased risk of bladder cancer and higher grade
tumors. In this study survivin sensitivity was 64%.
c
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onsistent with these previous reports, the present study find-
ngs revealed a significant increase of survivin protein content in
rine of the malignant group compared to the tumor-free group
n using both ELISA and WB assays. However, it did not signif-
cantly differ with respect to the low and high grades of bladder
umor.
rom the ROC curve, survivin ELISA sensitivity was found to be
4.57% whereas specificity was 100%. Upon using the WB detec-
ion assay lower sensitivity (55.3%) and lower specificity (93.33%)
ere reported. From the data presented here, the ELISA assay seems
o be more sensitive and more specific in detecting urine survivin
han the WB assay, though statistical comparison between the two
ethods using differences between AUC test showed a non signifi-
ant difference (P = 0.08). Similarly, in a direct comparison of both
urvivin protein detection assays, Kappler et al. [13], reported a
igher sensitivity and a stronger correlation to prognosis of survivin
LISA in detecting soft-tissue sarcoma (STS) patients compared
ith WB assay. This could be explained with the different detec-
ion limits. Another reason for differences between the two protein
etection assays could be the use of different antibodies, which rec-
gnize different antigen epitopes and may differ in their sensitivities
13].
hough urinary survivin levels did not correlate significantly with
umor grade, the findings obtained from the current study have pro-
ided further evidence that survivin detection is a highly specific
arker for bladder cancer. This is in accordance with Weikert et al.
25], who were able to detect survivin mRNA in urine of 68% (24/35)
f patients by RT-PCR, and announced urinary survivin as a highly
pecific biomarker for TCC detection, though it did not relate to
athologic stage or grade categories.
n line with the previous finding, Moussa et al. [26], and Hou et al.
27], reported the detection of survivin mRNA in cells isolated
rom urine sediments using RT-PCR and real time quantitative RT-
CR respectively. However, they stated that urinary survivin mRNA
ncreased progressively in accordance with the depth of TCC infiltra-
ion in the muscles. Recently, Eissa and co-workers [28], reported a
arked increase in the positivity rate of urine survivin mRNA in the
alignant group compared with the benign and healthy groups using
ualitative RT-nested PCR. They reported a sensitivity of 78.6%.
ompared with the aforementioned studies, the sensitivity of uri-
ary survivin for bladder cancer detection reported by our study
as lower than initially reported by Smith et al. [24] (100%) but
n good accordance with the recent study of Eissa et al. [28]. Upon
sing a biodot microfiltration detection system to detect survivin in
oided urine specimens, lower sensitivity (64%) and lower speci-
city (93%) were reported by Shariat and colleagues [12]. The
iscrepancy in results may be attributed to different sample sizes
nd types, as some of the current study cases were associated with
chistosomiasis.
egardless of whether survivin detection strategies in urine samples
re based on protein or mRNA analysis, they should yield compa-
able results since survivin is a short-lived non secreted protein and
etection is dependent on its abundance in exfoliated malignantussed above provide support to incorporating survivin expression
n urine as one of potential markers being developed for bladder
ancer detection.
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rinary survivin can be considered as a promising non-invasive
arker for early detection of recurrence of NMIBC. Although, the
esults of ELISA and WB detection methods were comparable, the
trongest diagnostic statement can be made using the more sensitive
LISA. Its expression in urine does not correlate with that in tumor
issue.
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